January 2026 delivered a strong start for femtech funding, with startups in the women's health sector collectively raising $314 million across at least 14 deals. The month's activity signals sustained investor appetite for women's health innovation despite broader venture market headwinds.

Why It Matters

At $314M in a single month, femtech funding is accelerating despite the sector historically capturing only about 1% of total health tech investment. Two unicorns (Pomelo at $1.7B, Midi Health at $1B) emerging within weeks of each other suggests the category is finally attracting growth-stage capital, not just seed rounds.

The largest round went to Pomelo Care, which raised $92 million in Series C funding led by Stripes, reaching a $1.7 billion valuation. The virtual maternity care platform now supports nearly 7% of all U.S. births and covers over 25 million lives. Its clinical outcomes data is striking: 37% reduction in preterm births, 46% reduction in ER utilization, and a 6.8-day reduction in NICU length of stay. CEO Marta Bralic Kerns stated: "We've demonstrated that when care is proactive, evidence-based, and accountable, we improve outcomes and costs come down."

Other notable rounds included Nanit ($50M for AI-powered infant health monitoring), Pee Safe ($32M Series C for period and personal care in India), Evaro ($25M Series A for healthcare-as-a-service), ShanX Medtech ($24M for antimicrobial UTI testing), and Luminate ($21M for home-based cancer treatment). European deal flow was also strong, with BrightHeart raising EUR 11M for AI-powered prenatal ultrasound and Bactolife securing over EUR 30M for gut health proteins.

Earlier-stage activity was equally vibrant: Feminai raised $6M seed for at-home breast cancer screening, Science&Humans secured CAD $10M Series A for hormone health, Xella Health raised $3.7M pre-seed for multi-omic testing, and India's Pinky Promise closed a $1M pre-seed for AI-enabled women's health.

This funding wave followed closely on FemHealth Ventures closing its oversubscribed $65 million Fund II in early January, bringing its AUM to $100 million. Managing Partner Maneesha Ghiya noted: "This raise reflects growing recognition that women's health innovation offers both substantial societal impact and compelling investment potential."

Sources

Update — 2026-03-14

Initial entry — story first created.